Abstract. The purpose of this research was to prepare and evaluate sustained release mucoadhesive tablets of Itraconazole. It is practically insoluble in aqueous fluids hence its solid dispersion with Eudragit E100 was prepared by spray drying. This was formulated in matrix of hydrophilic mucoadhesive polymers Carbopol 934P (CP) and Methocel K4M (HPMC). The formulation was optimized using a 3 2 factorial design. Amounts of CP and HPMC were taken as formulation variables for optimizing response variables i.e. mucoadhesion and dissolution parameters. The optimized mucoadhesive formulation was orally administered to albino rabbits, and blood samples collected were used to determine pharmacokinetic parameters. The solid dispersion markedly enhanced the dissolution rate of itraconazole. The bioadhesive strength of formulation was found to vary linearly with increasing amount of both polymers. Formulations exhibited drug release fitting Peppas model with value of n ranging from 0.61 to 1.18. Optimum combination of polymers was arrived at which provided adequate bioadhesive strength and fairly regulated release profile. The experimental and predicted results for optimum formulations were found to be in close agreement. The formulation showed C max 1898± 75.23 ng/ml, t max of the formulation was 2 h and AUC was observed to be 28604.9 ng h/ml
INTRODUCTION
Itraconazole is an oral antifungal agent with a broad spectrum of activity. Itraconazole is weakly basic (pK a =3.7) and highly hydrophobic (octanol/water partition coefficient at pH=8.1, log P=5.66) (1). Itraconazole is most effective when drug concentration is maintained above the minimum effective concentration (MEC) Studies in immuno-compromised patients have shown that plasma concentration below the MEC not only results in poor clinical response but may cause relapse of disease (2) . Itraconazole belongs to Biopharmaceutical Classification Systems Class II drugs categorized with low water solubility and high permeability (3) . Because of poor dissolution in the gastrointestinal tract, its oral administration is faced with large interindividual variations in bioavailability; therefore enhancing the dissolution rate of itraconazole is an important task for its formulation development (4) . Itraconazole has been formulated with various carriers such as Eudragit E100, HPMC, phosphoric acid and hydroxypropyl-β-cyclodextrin to improve dissolution (5) (6) (7) (8) .
Mucoadhesive drug delivery system by virtue of prolong the retention time in the stomach, by improves the oral bioavailability of the drug. The application of an optimization technique consisting of statistical design to pharmaceutical formulation development provides an efficient and economical method to acquire the necessary information to understand the relationship between controllable (independent) variables and performance dependent variables or responses (9) . The technique of optimization is well reported in the literature for the development of tablet formulations (10) (11) (12) .
This study aimed at developing mucoadhesive dosage forms containing a solid dispersion of itraconazole with Eudragit E100 investigate the effect of two independent variables i.e. amount of two swellable polymer: Methocel K4M (HPMC) and Carbopol 934P (CP) on in vitro release at the end of 8 h and adhesive strength (f) of mucoadhesive drug delivery system. The mucoadhesive tablets involves relatively more economical and less complicated technology vis-à-vis many other drug delivery devices such as osmotic and transdermal delivery systems using (computer-aided optimization technique incorporating 3 2 full factorial design).
MATERIALS AND METHODS
Itraconazole was a gift sample from Ranbaxy Pharmaceuticals, Jejury, India, Methocel K4M by Colorcon Asia Pvt. Ltd. (Goa, India), Carbopol 934P from M/s Loba Chemie Ltd. (Mumbai, India), Eudragit E100 was a gift sample from Degussa, India. Lactose from M/s Loba Chemie Ltd. (Mumbai, India) were procured from commercial sources. All other chemicals used in the study were of analytical grade.
Preparation of Solid Dispersion
Solid dispersion of itraconazole with Eudragit® E100 was prepared by spray drying technique (13) . Drug and carrier were dissolved in dichloromethane in different ratios and spray dried on Labultima laboratory spray dryer model LU 222. Following parameters were employed aspiration speed: 60, feed rate: 10 ml/min, inlet temperature: 80°C, outlet temperature: 40°C.
Characterization of Solid Dispersion

Solubility
The solubility of itraconazole in solid dispersion was investigated by a dispersion method using 0.1 N HCl. One hundred milligrams of a solid dispersion was added into a test tube containing 10 mL of the 0.1 N HCl (pH 1.2±0.1). The mixture was vortexed to disperse homogeneously and then centrifuged at 15,000×g for 20 min. The content of intraconazole in the supernatant, defined as the degree of solubility in this study, was measured by the UV spectrophotometric method at 254 nm.
Fourier Transform-Infrared Study. Fourier transform-infrared (FT-IR) spectra were measured using an IR spectrophotometer (Jasco). FT-IR spectra over the scanning range 400-3,600 cm −1 were obtained with the resolution of 2 cm
Diffferential Scanning Calorimetric Study of Solid Dispersion. Diffferential scanning calorimetric (DSC) study was done on solid dispersion, itraconazole and Eudragit E100 on Mettler Toledo Diffferential scanning calorimeter.
Preparation of Mucoadhesive Compressed Matrices
The composition of different mucoadhesive formulations prepared using varying amounts of CP (33-100 mg), HPMC (33-100 mg), with fixed quantity of micro crystalline cellulose (15 mg) and lactose (85 mg). Solid dispersion (300 mg) containing Itraconazole equivalent to 100 mg and excipients were homogeneously blended and subsequently compressed into flat-faced tablets (12 mm diameter) to achieve tablet hardness 7 to 8 kg/cm 2 .
Factorial Design
A 3 2 full FD was constructed where the amounts of CP (X 1 ) and HPMC (X 2 ) were selected as the factors. The levels of the two factors were selected on the basis of the preliminary studies carried out before implementing the experimental design. All other formulation and processing variables were kept invariant throughout the study.
Tablet Evaluation
Tablet Assay
Twenty tablets were powdered individually and a quantity equivalent to 100 mg of itraconazole was accurately weighed and extracted with a suitable volume of 0.1 N HCl. Each extract was suitably diluted and analyzed spectrophotometrically (Jasco V-530 UV/VIS Spectrophotometer) at 254 nm.
Physical Evaluation
Tablets were evaluated for uniformity in weight and thickness. Friability was measured using a Roche-type friabilator (Tropical Equipment Pvt. Ltd., Mumbai, India) and hardness using a Monsanto-type hardness tester (Campbell, Mumbai, India).
Ex vivo Bioadhesion Studies
The ex vivo adhesion studies were conducted using a modification of a test assembly described by Gupta et al. (14) . The porcine stomach mucosa was kept frozen in 0.1 N HCl and thawed to room temperature before use. The membrane was excised by removing the underlying connective and adipose tissue and was equilibrated at 37±0.5°C for 30 min in 0.1 N HCl before the study. The tablet was placed on mucosa under constant weight of 5 g for a total contact period of 1min. Bioadhesive strength was assessed in terms of weight (grams) required for detaching the tablet from the membrane.
In Vitro Release Study
Drug release studies (n=5) were conducted for all the formulation combinations using dissolution test apparatus (DA-6D USP Standard); 0.1 N HCl (900 ml) was taken as the release medium at 100 rpm and 37±0.5°C employing USP II paddle method (Apparatus II).
Data Analysis
The data obtained from dissolution kinetic studies were analyzed using PCP disso software (Poona College of Pharmacy, Pune, India.). The computed values of kinetic constant (k) and diffusional release exponent (n) were calculated using logarithmic transformation of the relationship proposed by Korsmeyer et al. as in Eq. 1 (15) .
Where M t /M ∞ is the fraction of drug released at time t. The values of t 50% were calculated. The influence of polymers on bioadhesive strength and in vitro release from tablet at the end of 8 h was investigated by two-way analysis of variance (ANOVA)-based factorial analysis followed by several one-way ANOVA.
Various computations for the current optimization study using Response Surface Methodology (RSM) were carried out, employing software, State Ease Design Expert Version 7. Statistical second-order model including interaction and polynomial terms were generated for all the response variables.
The general form of the model is represented as in Eq. 2.
Where β 0 the intercept, is the arithmetic average of all quantitative outcomes of nine runs, β 1 to β 8 are the coefficients computed from the observed experimental values of Y, and X 1 and X 2 are the coded levels of the independent variable(s). The terms X 1 X 2 and X 2 i i ¼ 1; 2 ð Þ are the interaction and polynomial terms, respectively. The statistical validity of the polynomials was established on the basis of Yates' ANOVA. Subsequently, feasibility as well as grid search was performed to locate the composition of optimum formulations. Also, three-dimensional response surface graphs and contour plots were drawn in MS-Excel using the output files generated by the State Ease Design Expert Version-7 software.
Validation of Optimization Model
Five optimum formulations were selected by intensive search, performed over the entire experimental domain, to validate the chosen experimental design and polynomial equations. The criterion for selection of optimum was primarily based on the highest possible values of the two response parameters namely percent drug released in 8 h and bioadhesive strength. The formulations corresponding to this optimum were prepared and evaluated for various response properties. The resultant experimental data of response properties were subsequently quantitatively compared with predicted values. Also, linear regression plots between observed and predicted values were prepared.
In Vivo Study of Optimized Formulation
In vivo evaluation was carried out in rabbits of the optimized formulation of itraconazole tablets to establish the bioavailability of the formulation (16) .
Five rabbits of either sex weighing (2.2-2.6 kg) were taken for in vivo studies of the optimum formulation. Food was withdrawn 72 h before drug administration. All rabbits had free access to water throughout the study. The institutional animal ethical committee approved the protocol for this study. Blood samples 1-2 ml (with anticoagulants) was collected by means of cannula from marginal ear vein at different intervals for 36 h. Plasma was immediately separated by centrifugation at 300-400 rpm for 10 min. This was then transferred to labeled tubes and was stored at −20°C until subsequent high performance liquid chromatography (HPLC) analysis.
At the end of study the animal was sacrificed and the stomach was opened to investigate the position of tablet in rabbit stomach.
High Performance Liquid Chromatography Analysis
High Performance Liquid Chromatography Instrumentation and Chromatographic Conditions
Jasco HPLC system, consisting of Jasco PU-2080 plus HPLC pump and Jasco UV-2075 plus UV/VIS detector and HiQ SiL C 18 (250×4.6 mm i.d.) column was used in analysis. A Rheodyne injector with 20 μl loop was used for injecting the sample. All weighing were done on Shimadzu balance (Model AY-120).
The mobile phase used was Acetonitrile: 10 mM KH 2 PO 4 (60:40) with pH adjusted to 7.8 with o-phosphoric acid with flow rate of 2.5 mL min −1 . UV detection was carried out at 263 nm.
Procedure
One hundred milligrams of Itraconazole was initially mixed with 100 μL of chloroform and then dissolved in 10 mL of dimethyl sulfoxide to yield stock solution of 10 mg mL 
Precision and Recovery Studies
Recovery studies were carried out to check accuracy of the method. Three replicate assays over three concentrations were performed containing known amounts of the analyte added to biological matrix sample. Precision was assessed at three concentration levels (n=3) on the same day as well as on three different days.
RESULTS
The spray dried solid dispersions of itraconazole and eudragit produced free flowing product, the ratio of itraconazole: eudragit was selected on basis of solubility study.
Solubility Study for Solid Dispersion
The solubility of itraconazole from solid dispersion containing 1:2 itraconazole: eudrajit enhanced to was 4 mg/ml in aqueous medium; the reported solubility of itraconazole at pH 1.2 was 0.57 mg/mL (6). The prepared solid dispersion was used in formulation of mucoadhesive tablet.
Fourier Transform-Infrared Analysis
FT-IR analysis of itraconazole, eudragit and solid dispersion was carried out in order to detect any interactions between itraconazole and Eudragit E100 (Fig. 1) in the range 400-4000 cm −1 . Major, specific FT-IR spectra of itraconazole powders were noticed at 400-1800 cm −1
. They might have arisen from the stretching and vibration of functional groups such as -C=C− of aromatic groups. A peak observed at 1600-1800 cm −1 is attributed to -C=O stretching and vibration, whereas peaks for alkane and amine groups were noticed at 2800-3200 cm −1 .
Diffferential Scanning Calorimetric Studies
In DSC the pure drug shows sharp endotherm at 167°C indicating the melting point of the pure drug. Same endotherm is seen in solid dispersion (Fig. 2) .
Factorial Design
Preliminary studies carried out prior to the experimental design revealed that the tablet formed with low polymer content exhibited 100% drug release, but was vulnerable to fragmentation. On the other hand, the tablet formed with very high polymer content possessed good structural integrity, but showed undesirably slow release. Accordingly, a suitable range for each of the polymer amounts was selected.
Design of experiment has been widely used in pharmaceutical field to study the effect of formulation variables and their interactions on response variables. Table I summarizes the experimental runs, their factor combinations, and the translation of the coded levels to the experimental units used in the study.
Tablet Evaluation
The assay content of itraconazole varied between 98.2% and 99.8%.
Physical Evaluation. Tablet weights varied between 595 and 605 mg, thickness between 3 to 4 mm, and hardness between 6.5 and 7.5 kg/cm 2 and the friability ranged between 0.3% and 0.6%. Ex Vivo Bioadhesion Strength Determination. Maximum bioadhesive strength (f) was seen with the highest level of the two polymers. Application of two-way ANOVA based factorial analysis indicated that the polymers had a significant influence on the bioadhesive properties of the compressed matrices (ρ < 0.001). Subsequent application of one-way ANOVA, keeping the levels of one of the polymers fixed, also showed a statistically significant difference amongst the observed data of bioadhesive strength (ρ<0.001), ratifying the significant positive influence of each polymer on bioadhesion. Table II lists Table II lists the dissolution kinetics parameters computed for nine trial runs. The in vitro release profiles of the drug for all the formulations could be best expressed by 'Peppas' equation formulations also showed high linearity (R 2 = −0.9985), with a comparatively high slope (n) value ranging from 0.6111 to 1.1761. The, value of kinetic constant (k) ranged from 5.98 to 29.67. Figure 3 shows dissolution profile from all nine formulations prepared as per 3 2 full factorial designs.
In Vitro Release Studies
Optimization Results
The mathematical relationships constructed for the studied response variables are expressed as Eqs. 3-4. All the polynomial equations were found to be highly statistically significant (ρ<0.001), as determined by ANOVA, %Release ¼ 91:69 À 4:60X 1 À 7:75X 2 À 1:63X 1 X 2 À0:56X The dissolution parameters of all the five optimum formulations, value of n ranged from 1.13 to 1.21, indicating super class II transport. The value of kinetic constant was varied from 5.07 to 6.15 indicating that Peppas as the best fitting model for all optimized mucoadhesive formulation, % Rel 8h ranged between 71% to 77% (Fig. 6) .
For all these formulations, the bioadhesive strength ranged between 23.08 to 25.35 g. The hydrogels are known to swell readily when they come in contact with hydrated mucous membrane. The water sorption reduces the glass transition temperature below the ambient conditions and hydrogels become progressively rubbery due to uncoiling of polymer chains and subsequent increased mobility of the polymer chains. This glass-rubbery transition provides hydrogel plasticization resulting in large adhesive surface for maximum contact with mucin and flexibility to the polymer chains for interpenetration with mucin. Increasing the polymer amount may provide more adhesive sites and polymer chains for interpenetration with mucin, resulting consequently in the aggrandization of bioadhesive strength. Although the maximum value of bioadhesive strength is attained at the highest levels of both the polymers, yet the effect of CP 934P is more pronounced than of HPMC K4M. Table III records the values of observed and predicted responses using factorial design along with the percentage predicted errors for these six optimum formulations. The predicted error for the response variables ranged between 2.12% and 0.62%, with the mean ± SD of the percentage error being -0.13±0.7397%.
Validation of Optimization Model
In-vivo Study
Pharmacokinetic study was conducted on rabbits dosed with optimized itraconazole mucoadhesive tablets.
A chromatogram of Itraconazole is shown in Fig. 7 . A linear relationship was established between the peak area and Itraconazole in the concentration range of 0.1 and 20 μg mL The prepared mucoadhesive formulation exhibited C max 1898±75.23 ng/ml which is comparable to reported value of standard formulation sporanox (16) , t max of the formulation was 2 h. The plasma concentrations of itraconazole were followed for 48 h and the AUC was observed to be 28,604.9 ng h/ml (Fig. 8) , which is slightly better as compared to reported value for sporanox (23,382.2±6,326). The tablet was found retained in stomach adhering to epithelial lining when animal was sacrificed at the end of experiment (Fig. 9) .
DISCUSSION
The itraconazole solubility from solid dispersions was increased by eight times. The state of itraconazole in solid dispersions with eudragit E100 is reported as amorphous and exists as molecular dispersion in eudragit E100 which is responsible for the increase in the solubility (17) .
Major peaks observed in Eudragit E100 and itraconazole were also observed in the solid dispersion at 400-4,000 cm −1 . Thus FT-IR analysis of itraconazole and solid dispersion with eudragit E100 suggested the absence of any significant interactions. Further DSC studies also indicate absence of significant interactions, as presence of endothermic peak at 167°C in both pure drug and solid dispersion thermograms.
An increase in the amount of polymer will increase the bioadhesive strength; mucoadhesive strength also depends upon molecular weight, contact time and pH (14) . Increased mucoadhesive strength is reported when the polymers are used in combination (18) .
Although tablets containing hydroxypropyl cellulose and carbopol were shown to have less bioadhesion due to complex formation (19) , no complex formation was noticed in present investigation as seen in IR, thus showing additive effect on bioadhesion.
Data Analysis. The dissolution kinetics followed Peppas model. The value of n indicates a coupling of diffusion and erosion mechanisms also called anomalous diffusion. The relative complexity of this formulation and its components may indicate that the drug release is controlled by more than one process. An increase in the amount of polymer will decrease the drug release hence lower value of the drug release constant (k) at high polymer content was obtained. Sustained drug release was seen at highest levels of the two polymers. Application of two-way ANOVA based factorial analysis indicated that the polymers had a significant influence on the release of drug from the compressed matrices (ρ < 0.05). Subsequent application of one-way ANOVA, keeping the levels of one of the polymers fixed, also showed a statistically significant difference amongst the observed data of dissolution (ρ<0.05), ratifying the significant positive influence of each polymer on dissolution. a mixture of HPMC with CP 934P resulted in the reduction of polymer viscosity due to reduced hydration. This reduction of viscosity could facilitate drug diffusion through polymer hydrogel. Evidently, the values of dissolution parameters had a propensity to range optimally between relatively controlled limits rather than those of the original formulations designed as per 3 2 factorial designs. The release profile of optimum formulation is seen in Fig. 6 . Finally the in vivo study indicates a similar t max and C max to that of reported value of immediate release sporanox but subsequently the drug release was prolonged and showed higher AUC.
CONCLUSION
The mucoadhesive polymers carbopol and HPMC are more effective in combination than alone. Suitable combination of the two optimized using 3 2 full factorial design showed good agreement between predicted and observed responses. The in vitro drug release was zero order. The in vivo studies confirmed sustained drug release and gastric retention for six hours. Thus suitable combination of mucoadhesive polymers can be used to achieve desired gastric retention and drug release profile.
